UBS/CALL/ROCHE GS/340.004/0.025/20.12.24 Stock

Warrant

UYROGU

CH0589942454

Real-time Bid/Ask 05:13:40 2024-06-03 am EDT
0.012 CHF / 0.031 CHF -15.38% Intraday chart for UBS/CALL/ROCHE GS/340.004/0.025/20.12.24
3 months-39.53%
6 months-50.94%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Static data

Product typeWarrants
Buy / SellCALL
Underlying ROCHE HOLDING AG
Issuer UBS
UYROGU
ISINCH0589942454
Date issued 2021-01-13
Strike 340 CHF
Maturity 2024-12-20 (201 Days)
Parity 40 : 1
Emission price 0.53 CHF
Emission volume N/A
Settlement physique
Currency CHF

Technical Indicators

Highest since issue 1.95 CHF
Lowest since issue 0.02 CHF
Delta0.05x
Omega 12.55
Premium46.67x
Gearing270.23x
Moneyness 0.6835
Difference Strike 107.8 CHF
Difference Strike %+31.71%
Spread 0.019 CHF
Spread %61.29%
Theoretical value 0.0215
Implied Volatility 28.13 %
Total Loss Probability 97.06 %
Intrinsic value 0.000000
Present value 0.0215
Break even 340.86 CHF
Theta-0x
Vega0x
Rho0x

Company Profile

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Sector
-
More about the company

Ratings for Roche Holding AG

Trading Rating
Investor Rating
ESG Refinitiv
A+
More Ratings

Consensus: Roche Holding AG

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
20
Last Close Price
231 CHF
Average target price
277.5 CHF
Spread / Average Target
+20.14%
Consensus
  1. Stock Market
  2. Warrants
  3. UYROGU Warrant